ASBP
Aspire Biopharma Holdings, Inc. (ASBP) ESG Analysis Analysis (2026)
No material changes this month.
Overall Score
Environmental
No material environmental disclosures or sustainability metrics were provided in the latest data.
The company’s capital-light profile is reflected in zero capex-to-revenue and zero capex-to-depreciation, which limits near-term environmental intensity from fixed-asset investment.
Social
No material social disclosures or workforce/community metrics were provided in the latest data.
Very high SG&A-to-revenue suggests a service-heavy cost structure, but there is no direct evidence of employee, customer, or community ESG improvement or deterioration this month.
Governance
Balance-sheet liquidity remains strong with a current ratio of 7.99 and cash ratio of 7.22, supporting financial resilience.
However, profitability remains weak with negative operating margin, negative net margin, and negative interest coverage, which keeps governance/financial discipline concerns elevated.
No debt burden is shown in the latest ratios, with debt-to-assets and debt-to-equity both at 0, reducing leverage risk.
Risk
Sustained losses and negative operating cash flow remain the primary risk, with EBIT margin at -64.7% and operating cash flow sales ratio at -73.6%.
The company’s extremely low scale and negative enterprise value can make ESG assessment less informative because small absolute changes can swing ratios materially.
No new litigation, regulation, or controversy items were reported in recent news this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.